G6PD and prostate carcinoma: Bone metastatic PC3 prostate cancer cells were found to have higher levels of the antioxidant glutathione (GSH) when compared to non–bone metastatic LNCaP cells, along with higher G6PD (Figs. 2, A and B, and 5A).